Pasithea Therapeutics (KTTA) Equity Ratio (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Equity Ratio for 4 consecutive years, with 0.96 as the latest value for Q3 2024.
- Quarterly Equity Ratio rose 3.27% to 0.96 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was 0.96 through Sep 2024, up 3.27% year-over-year, with the annual reading at 0.9 for FY2023, 4.75% down from the prior year.
- Equity Ratio hit 0.96 in Q3 2024 for Pasithea Therapeutics, up from 0.92 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.98 in Q1 2022 to a low of 0.78 in Q3 2021.
- Historically, Equity Ratio has averaged 0.92 across 4 years, with a median of 0.93 in 2023.
- Biggest five-year swings in Equity Ratio: grew 20.46% in 2022 and later decreased 4.87% in 2023.
- Year by year, Equity Ratio stood at 0.96 in 2021, then decreased by 2.46% to 0.94 in 2022, then fell by 4.75% to 0.9 in 2023, then grew by 6.68% to 0.96 in 2024.
- Business Quant data shows Equity Ratio for KTTA at 0.96 in Q3 2024, 0.92 in Q2 2024, and 0.89 in Q1 2024.